BOTOX secured its first FDA approval more than 22 years ago as a treatment for two rare eye muscle disorders, making it the first product of its kind approved in the world. In 2002, the same formulation with dosing specific to frown lines was approved under the name BOTOX Cosmetic.
"The FDA approval of BOTOX Cosmetic enhanced the practice of plastic surgery by providing plastic surgeons with a new treatment option for patients seeking to reduce the appearance of vertical frown lines between the eyebrows," said Malcolm Z. Roth, MD, president of the American Society of Plastic Surgeons.
In the decade since BOTOX Cosmetic was approved, aesthetic specialty physicians — which include dermatologists, oculoplastic surgeons and facial plastic surgeons — have developed extensive experience in the art and science of administering BOTOX® Cosmetic to yield predictable results for their patients. These physicians have performed approximately 11 million BOTOX® Cosmetic treatment sessions since 2002 and have also contributed to the extensive clinical database demonstrating the safety and efficacy of the drug.
"The approval of BOTOX Cosmetic in 2002 dramatically changed our ability to treat our patients by giving them an effective option to treat the appearance of moderate to severe vertical frown lines with a minimally invasive procedure," said Susan Weinkle, MD, president of the American Society for Dermatologic Surgery. "BOTOX Cosmetic has become more accepted by the public, and this treatment has brought more patients into aesthetic practices to learn about other treatments available."
Derma Health of Arizona is a Black Diamond Provider of Allergan BOTOX, which means we are one of the largest providers of BOTOX in the nation and the number one provider of BOTOX in Arizona. What does that mean to you? It means you have the best doctors and nurses with the highest level of experience in performing these procedures.
About BOTOX®
BOTOX® is a prescription-only medical product that contains tiny amounts of highly purified botulinum toxin protein refined from the bacterium, Clostridium botulinum. BOTOX® has a unique, protected molecular structure that stabilizes the core toxin in BOTOX® from degradation. When injected at FDA-approved and labeled doses into a specific muscle or gland, BOTOX® is expected to diffuse locally and produce a safe and effective result by producing a localized and temporary reduction in the overacting muscle or gland, usually lasting up to approximately three to ten months depending on the indication and on the individual patient.

IRVINE, Calif.--(BUSINESS WIRE)-- Allergan, Inc. (NYSE: AGN) announced today that April 15, 2012 will mark the 10-year anniversary of the U.S. Food and Drug Administration's (FDA) approval of BOTOX Cosmetic to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.